| Discuss | Index | Tracked By |
The Unusual Suspects
HAS PFE TIF AMGN OSIP BBY ADBE TEVA CSCO LGF CIEN RIMM AIXG PALM GME SOMX ORCL Linked by 24/7 Wall St. ( track newsfeed | ignore newsfeed ) - March 20, 10:58AM from (247wallst.com) This week is a jam packed list full of the Unusual Suspects. We have many earnings reports, enough that we had to screen more ...
Getting Into Gold And Dendreon Volatility
BAC BBY GS JBL DNDN GLD Linked by Forbes ( track newsfeed | ignore newsfeed ) - March 19, 03:43PM from (www.forbes.com) A down day for gold inspires some bulls to load up on calls. more ...
BioHealth Business Daily
MRK OSIP GENZ CLDX APPA OXGN THRX GENT SOMX Linked by 24/7 Wall St. ( track newsfeed | ignore newsfeed ) - March 19, 12:39PM from (247wallst.com) We are seeing many key movers in the BioHealth space today as drug and biotech stocks often exhibit the most volatility of more ...
Seattle Genetics initiated with "hold"
SGEN Linked by newratings ( track newsfeed | ignore newsfeed ) - March 19, 12:13PM from (www.newratings.com) NEW YORK, March 19 (newratings.com) - Analysts at Brean Murray initiate coverage of Seattle Genetics Inc (ticker: SGEN) with more ...
BioHealth Business Daily
OSIP APPA TEVA ARIA MDVN SOMX Linked by 24/7 Wall St. ( track newsfeed | ignore newsfeed ) - March 18, 02:50PM from (247wallst.com) These are some of the top movers in the world of BioHealth investing. It is usual that drug companies and biotech stocks more ...
Abraxis Flies On Drug Test Success
DNA OSIP AZN RHHBY ABII Linked by Forbes ( track newsfeed | ignore newsfeed ) - March 17, 04:13PM from (www.forbes.com) Biotechnology company gains on successful late-stage study for lung cancer treatment. more ...
GTx downgraded to "market underperform"
GTXI Linked by newratings ( track newsfeed | ignore newsfeed ) - March 17, 03:13PM from (www.newratings.com) NEW YORK, March 17 (newratings.com) - Analysts at Rodman & Renshaw downgrade GTx Inc (ticker: GTXI) from "market more ...
Human Genome Sciences Sags on Downbeat Drug Data
HGSI Linked by BloggingStocks ( track newsfeed | ignore newsfeed ) - March 17, 01:13PM from (www.bloggingstocks.com) Human Genome Sciences (HGSI) slipped into the red right out of the gate Wednesday morning, as traders reacted to the company's more ...
Abraxis Finds The Right Dose
DNA OSIP RHHBY ABII Linked by Forbes ( track newsfeed | ignore newsfeed ) - March 17, 12:43PM from (www.forbes.com) Successful trial of lung cancer drug sends biotech's shares spiraling higher. more ...
BioHealth Business Daily
LLY STEM SHPGY LXRX XNPT JAZZ GTXI MIPI ABII Linked by 24/7 Wall St. ( track newsfeed | ignore newsfeed ) - March 17, 11:53AM from (247wallst.com) We are seeing many key movers in the BioHealth space today. Biotech stocks and drug stocks are frequently more volatile more ...
Cytokinetics Announces Changes to Its Board of Directors
CYTK Linked by marketwire ( track newsfeed | ignore newsfeed ) - March 16, 04:43PM from (www2.marketwire.com) Cytokinetics, Incorporated (NASDAQ: CYTK) announced the resignation of James H. Sabry, M.D., Ph.D., Co-founder and former more ...
ADVENTRX Pharma Narrows Q4 Loss Y/Y
ANX Linked by StreetInsider ( track newsfeed | ignore newsfeed ) - March 16, 08:52AM from (www.streetinsider.com) more ...
ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
ANX Posted by PR Newswire ( track newsfeed | ignore newsfeed ) - March 16, 08:30AM SAN DIEGO, March 16 /PRNewswire-FirstCall/ -- ADVENTRX more ...
Ariad Pharma Posts Q4 Loss of $0.17, In-Line with Views
ARIA Linked by StreetInsider ( track newsfeed | ignore newsfeed ) - March 16, 07:41AM from (www.streetinsider.com) more ...
Merck And GTx Go Their Separate Ways
MRK ALKS AMLN MNKD GTXI Linked by Forbes ( track newsfeed | ignore newsfeed ) - March 15, 05:43PM from (www.forbes.com) Pair will end partnership on cancer drug, leaving GTx with rights, and costs, of development. more ...
OSI Plays Hard To Get
WYE MRK PFE DNA OSIP GILD CVTX Linked by Forbes ( track newsfeed | ignore newsfeed ) - March 15, 05:13PM from (www.forbes.com) Biotech rejects unsolicited $3 billion bid from Japan's Astellas Pharma, says it would entertain a higher offer. more ...
U.S. Debt Worries Dent Wall Street
XOM PEP PVH CVX WMT D OSIP BSX MCO CNX Linked by Forbes ( track newsfeed | ignore newsfeed ) - March 15, 01:13PM from (www.forbes.com) Moody's warns of sovereign debt rating, stocks bear the brunt. more ...
Stocks Teeter On Industrial Production
KO PEP PVH WMT OSIP CCE PBG PAS Linked by Forbes ( track newsfeed | ignore newsfeed ) - March 15, 10:43AM from (www.forbes.com) U.S. equities slip early Monday, despite better-than-expected economic data. more ...
Progenics Pharma Posts Q4 Loss of $0.02, Narrower than Views
PGNX Linked by StreetInsider ( track newsfeed | ignore newsfeed ) - March 15, 09:15AM from (www.streetinsider.com) more ...
Progenics Announces Fourth Quarter and Year-End 2009 Financial Results
PGNX Linked by BusinessWire ( track newsfeed | ignore newsfeed ) - March 15, 09:00AM from (www.businesswire.com) Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the fourth quarter and year more ...
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Home | About | Register | My tickerspy | Logout | Web site design by LightMix |
| © 2010 Indie Research, LLC. All rights reserved. | |
---
Institutional Holdings Disclaimer Pro portfolios track the top 15 quarterly holdings of more than 1,400 institutions. Comments in Pro portfolios show the institution's change in shares held for each company quarter over quarter. Pro portfolio performance is based on institutions' top 15 holdings as disclosed in quarter-end filings with the SEC. Pro performance does not take into account additional holdings beyond the top 15 nor does it include positions that are not required to be disclosed by the SEC. As such, Pro portfolio performance should be considered an approximation and not a precise record of how an institution has performed over time. tickerspy is not affiliated with any of the Pro investors profiled on our web site. The performance data and graph are estimates and do not represent an advertisement or endorsement by either tickerspy or the Pro investors. THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED "AS IS" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, INDIE RESEARCH, LLC AND IT LICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS AND NON-INFRINGEMENT. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER INDIE RESEARCH, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICNESORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGAES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.
|
|